{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:49:10Z","timestamp":1782827350460,"version":"3.54.5"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMS"},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["T32 5T32DK060414-14"],"award-info":[{"award-number":["T32 5T32DK060414-14"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.bpg.2017.06.002","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T22:02:03Z","timestamp":1496959323000},"page":"311-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Management of hepatitis B in special populations"],"prefix":"10.1016","volume":"31","author":[{"given":"Kali","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bpg.2017.06.002_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hep.1840030201","article-title":"Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial","volume":"3","author":"Beasley","year":"1983","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2017.06.002_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2013.11.008","article-title":"Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers","volume":"60","author":"Yi","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2017.06.002_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5694\/j.1326-5377.2009.tb02524.x","article-title":"Perinatal transmission of hepatitis B virus: an Australian experience","volume":"190","author":"Wiseman","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.bpg.2017.06.002_bib4","series-title":"Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection","author":"WHO","year":"2015"},{"issue":"11","key":"10.1016\/j.bpg.2017.06.002_bib5","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1136\/gutjnl-2014-308211","article-title":"Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B","volume":"64","author":"Giles","year":"2015","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.bpg.2017.06.002_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/ajg.2016.296","article-title":"Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B","volume":"111","author":"Chang","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.bpg.2017.06.002_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jcv.2012.11.019","article-title":"Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus","volume":"56","author":"Kim","year":"2013","journal-title":"J\u00a0Clin Virol"},{"issue":"3","key":"10.1016\/j.bpg.2017.06.002_bib8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2893.2007.00894.x","article-title":"Exacerbation of chronic hepatitis B infection after delivery","volume":"15","author":"Ter Borg","year":"2008","journal-title":"J\u00a0Viral Hepat"},{"issue":"4","key":"10.1016\/j.bpg.2017.06.002_bib10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3748\/wjg.v21.i4.1261","article-title":"Post-partum reactivation of chronic hepatitis B virus infection among hepatitis B e-antigen-negative women","volume":"21","author":"Elefsiniotis","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.bpg.2017.06.002_bib11","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/apt.12726","article-title":"Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare","volume":"39","author":"Nguyen","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.06.002_bib13","unstructured":"http:\/\/www.apregistry.com\/forms\/interim_report.pdf."},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.28302","article-title":"Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis","volume":"63","author":"Brown","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2017.06.002_bib15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/QAD.0000000000001364","article-title":"In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy\/HIV-exposed infants: author's reply","volume":"31","author":"Denneman","year":"2017","journal-title":"AIDS"},{"issue":"13","key":"10.1016\/j.bpg.2017.06.002_bib16","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0000000000001156","article-title":"In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy\/HIV-exposed infants","volume":"30","author":"Denneman","year":"2016","journal-title":"AIDS"},{"issue":"12","key":"10.1016\/j.bpg.2017.06.002_bib17","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/cid\/ciw159","article-title":"Utero tenofovir exposure is not associated with fetal long bone growth","volume":"62","author":"Jao","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.bpg.2017.06.002_bib18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3851\/IMP1909","article-title":"In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers","volume":"16","author":"Vigano","year":"2011","journal-title":"Antivir Ther"},{"issue":"5","key":"10.1016\/j.bpg.2017.06.002_bib19","doi-asserted-by":"crossref","first-page":"e1001217","DOI":"10.1371\/journal.pmed.1001217","article-title":"Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial","volume":"9","author":"Gibb","year":"2012","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.bpg.2017.06.002_bib21","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2017.06.002_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/hep.27837","article-title":"Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus","volume":"62","author":"Chen","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2017.06.002_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/gutjnl-2015-310317","article-title":"Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders","volume":"65","author":"Visvanathan","year":"2016","journal-title":"Gut"},{"issue":"38","key":"10.1016\/j.bpg.2017.06.002_bib24","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.3748\/wjg.v17.i38.4321","article-title":"A\u00a0meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus","volume":"17","author":"Han","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2017.06.002_bib25","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/j.1365-2893.2011.01492.x","article-title":"Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers","volume":"19","author":"Zou","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"issue":"24","key":"10.1016\/j.bpg.2017.06.002_bib26","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2017.06.002_bib27","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/hep.28310","article-title":"Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection","volume":"63","author":"Fan","year":"2016","journal-title":"Hepatology"},{"issue":"231","key":"10.1016\/j.bpg.2017.06.002_bib28","first-page":"e1","article-title":"Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis","volume":"207(3)","author":"Nayeri","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.bpg.2017.06.002_bib29","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.cgh.2013.04.026","article-title":"Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants","volume":"11","author":"Pan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2017.06.002_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/cid\/ciu798","article-title":"Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence","volume":"60","author":"Ehrhardt","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.bpg.2017.06.002_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3851\/IMP2739","article-title":"Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN study","volume":"19","author":"Corbett","year":"2014","journal-title":"Antivir Ther"},{"issue":"12","key":"10.1016\/j.bpg.2017.06.002_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2893.2009.01249.x","article-title":"Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007","volume":"17","author":"Spradling","year":"2010","journal-title":"J\u00a0Viral Hepat"},{"issue":"6","key":"10.1016\/j.bpg.2017.06.002_bib33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","article-title":"Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort","volume":"19","author":"Konopnicki","year":"2005","journal-title":"AIDS"},{"issue":"5 Suppl","key":"10.1016\/j.bpg.2017.06.002_bib34","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1002\/hep.22883","article-title":"Hepatitis B and human immunodeficiency virus coinfection","volume":"49","author":"Thio","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2017.06.002_bib35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(07)70135-4","article-title":"Clinical implications of HIV and hepatitis B co-infection in Asia and Africa","volume":"7","author":"Hoffmann","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.bpg.2017.06.002_bib36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/ajg.2008.159","article-title":"Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination","volume":"104","author":"Sun","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2017.06.002_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00002030-199705000-00007","article-title":"Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection","volume":"11","author":"Gilson","year":"1997","journal-title":"AIDS"},{"issue":"24","key":"10.1016\/j.bpg.2017.06.002_bib38","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1002\/cncr.27694","article-title":"The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States","volume":"118","author":"Sahasrabuddhe","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bpg.2017.06.002_bib39","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bpg.2017.06.002_bib40","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.bpg.2017.06.002_bib41","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1086\/599110","article-title":"Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis","volume":"48","author":"Nikolopoulos","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.bpg.2017.06.002_bib42","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1086\/420744","article-title":"Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic","volume":"38","author":"Sheng","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bpg.2017.06.002_bib43","series-title":"Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: HBV infection","year":"2017"},{"key":"10.1016\/j.bpg.2017.06.002_bib44","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Hepatitis B\/HIV Coinfection. Available at: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf."},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2893.2010.01275.x","article-title":"Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV\/HBV-coinfected patients","volume":"18","author":"Miailhes","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"issue":"6","key":"10.1016\/j.bpg.2017.06.002_bib46","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1053\/j.gastro.2010.08.045","article-title":"Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus","volume":"139","author":"de Vries-Sluijs","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib47","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/00002030-200301030-00002","article-title":"An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals","volume":"17","author":"Nelson","year":"2003","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.bpg.2017.06.002_bib48","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1681\/ASN.2012080857","article-title":"Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?","volume":"24","author":"Tourret","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"10.1016\/j.bpg.2017.06.002_bib50","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1056\/NEJMoa067710","article-title":"The HBV drug entecavir \u2013 effects on HIV-1 replication and resistance","volume":"356","author":"McMahon","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.bpg.2017.06.002_bib51","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/gast.2002.37061","article-title":"Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B","volume":"123","author":"Di Martino","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2017.06.002_bib52","series-title":"The twin epidemics of substance abuse and HIV","year":"1991"},{"issue":"9","key":"10.1016\/j.bpg.2017.06.002_bib53","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/cid\/cit002","article-title":"Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus","volume":"56","author":"Matthews","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QAI.0000000000000126","article-title":"Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort","volume":"66","author":"Kim","year":"2014","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.bpg.2017.06.002_bib55","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/hep.27182","article-title":"Persistent viremia in human immunodeficiency virus\/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications","volume":"60","author":"Boyd","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.bpg.2017.06.002_bib56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/135965350501000612","article-title":"Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir","volume":"10","author":"Sheldon","year":"2005","journal-title":"Antivir Ther"},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bpg.2017.06.002_bib58","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/10428190500062932","article-title":"Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations","volume":"46","author":"Law","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bpg.2017.06.002_bib59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.bpg.2017.06.002_bib60","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis","volume":"22","author":"Mozessohn","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"issue":"16","key":"10.1016\/j.bpg.2017.06.002_bib61","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2015.2571","article-title":"Preventing hepatitis B reactivation due to immunosuppressive drug treatments","volume":"313","author":"Perrillo","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.bpg.2017.06.002_bib62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2012.10.016","article-title":"Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes","volume":"58","author":"Burra","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.bpg.2017.06.002_bib63","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.28923","article-title":"Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy","volume":"65","author":"Flemming","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bpg.2017.06.002_bib64","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.1840130402","article-title":"Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease","volume":"13","author":"Todo","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.bpg.2017.06.002_bib65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/hep.1840130122","article-title":"Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis","volume":"13","author":"Davies","year":"1991","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bpg.2017.06.002_bib66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-6143.2012.04315.x","article-title":"High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver\u00a0transplantation: a systematic review","volume":"13","author":"Cholongitas","year":"2013","journal-title":"Am J Transpl"},{"key":"10.1016\/j.bpg.2017.06.002_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/hep.29191","article-title":"Long term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years","author":"Fung","year":"2017","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.bpg.2017.06.002_bib68","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/tri.12370","article-title":"New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence","volume":"27","author":"Cholongitas","year":"2014","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.bpg.2017.06.002_bib69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jhep.2011.04.002","article-title":"Individualizing hepatitis B infection prophylaxis in liver transplant recipients","volume":"55","author":"Fox","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.bpg.2017.06.002_bib70","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/TP.0000000000000777","article-title":"Rational basis for optimizing short and long-term hepatitis B virus prophylaxis post liver transplantation: role of hepatitis B immune globulin","volume":"99","author":"Roche","year":"2015","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.bpg.2017.06.002_bib71","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/TP.0000000000001171","article-title":"Early introduction of subcutaneous hepatitis B immunoglobulin following liver transplantation for hepatitis B virus infection: a prospective, multicenter study","volume":"100","author":"De Simone","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.bpg.2017.06.002_bib72","first-page":"677","article-title":"Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: a prospective, observational, multicenter study","volume":"18","author":"Klein","year":"2013","journal-title":"Ann Transpl"},{"key":"10.1016\/j.bpg.2017.06.002_bib73","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000001786","article-title":"Short course of post-operative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients 2017","author":"Radhakrishnan","year":"2017","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.bpg.2017.06.002_bib74","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/ctr.12804","article-title":"The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence","volume":"30","author":"Idilman","year":"2016","journal-title":"Clin Transpl"},{"issue":"25","key":"10.1016\/j.bpg.2017.06.002_bib75","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen","volume":"329","author":"Samuel","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.bpg.2017.06.002_bib76","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1600-6143.2010.03070.x","article-title":"Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients","volume":"10","author":"Coffin","year":"2010","journal-title":"Am J Transpl"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2017.06.002_bib77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2893.2007.00916.x","article-title":"Management of hepatitis B in liver transplant recipients","volume":"14","author":"Coffin","year":"2007","journal-title":"J\u00a0Viral Hepat"},{"issue":"11","key":"10.1016\/j.bpg.2017.06.002_bib78","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/lt.21882","article-title":"Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation","volume":"15","author":"Saab","year":"2009","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.bpg.2017.06.002_bib79","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2008.02.064","article-title":"Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation","volume":"134","author":"Faria","year":"2008","journal-title":"Gastroenterology"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691817300616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691817300616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T02:00:05Z","timestamp":1750298405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691817300616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1521691817300616"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2017.06.002","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of hepatitis B in special populations","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2017.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}